Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-122A for Ventilator-Associated Pneumonia
2023-508825-29-00Phase 2Withdrawn
- Sponsor
- TechnoPhage
- Start
- Feb 2024
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of TP-122 in ventilator-associated pneumonia (VAP) and Pseudomonal infection (2 arms), sponsored by TechnoPhage. Primary endpoints: Safety and tolerability: adverse events, Safety and tolerability: clinical laboratory parameters and 2 more. Planned start Feb 2024; status: withdrawn.
02
Drugs
TP-122
03
Conditions
ventilator-associated pneumonia (VAP)Pseudomonal infection
Beyond the preview
Go deeper on 2023-508825-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508825-29-00.